17,261 trials
Anemia · Leukemia · Lymphoma
Primary: The Percentage of Participants Who Exhibit a Hematopoietic Response — 68.9; 61.7; 65.5; 66.7 Percentage of participants — p=>0.41
Pain, Fracture, Sprain
Primary: Time to Analgesia — 10; 35 minutes
Botulism
Primary: Four-Fold Increase in Neutralizing Antibody Concentration (NAC) — 0.75; 0.84; 0.75; 0.89 proportion of participants
Acute Lymphoblastic Leukemia
Primary: Phase I: Number of Participants With Dose-limiting Toxicities (DLTs) — 0; 1; 2; 1 participants
Gonorrhoea
Primary: Number of Participants With Microbiological Cure at Urethral or Cervical Sites in Each Study Arm — 55; 54; 28 Participants
Parkinson Disease · Movement Disorders · Central Nervous System Diseases
Primary: Change From Baseline to Endpoint of 12 Weeks in the 3-day Average of Awake Time Per Day Spent in the "Off" State — -0.4; -1.3; -1.6; -1.7 hours/day — p=0.753
Ischemic Stroke · Transient Ischemic Attack
Primary: Number of Participants With Intracranial Bleeding and/or Recurrent Ischemic Lesion as Confirmed by MRI Imaging — 47; 48 Participants
Schizophrenia Prodrome
Primary: Scale of Prodromal Symptoms (SOPS) Negative Scale — 7.6; 11.3 SOPS negative final score — p=0.03
Breast Cancer
Primary: Change in Breast Epithelial Cell Proliferation as Measured by Ki-67 Labeling — .325; .289; -.418; -.461 Ki-67 labeling index
Rectal Cancer
Primary: Pathologic Complete Response Rate — 7 participants
Biliary Tract Cancer · Gallbladder Adenocarcinoma
Primary: Median Progression Free Survival — 7.0 months — p=<0.05
Hepatocellular Carcinoma
Primary: Maximum Tolerated Dose of RAD001 in Patients With Advanced Hepatocellular Carcinoma (HCC). — 10 mg — p=0.05
Lymphoma
Primary: Overall Response Rate — 53.3; 76.1 percentage of participants — p=0.29
Chemotherapy-induced Nausea and Vomiting
Primary: Complete Response Rate for Delayed Chemotherapy Induced Nausea & Vomiting — 13 participants
Ovarian Cancer
Primary: Occurrence of a DLT (Dose Limiting Toxicity) — 0; 1 Participants